ENTRY       D09315                      Drug
NAME        Canakinumab (USAN/INN);
            Canakinumab (genetical recombination) (JAN);
            Ilaris (TN)
PRODUCT     ILARIS (Novartis Pharmaceuticals Corporation)
FORMULA     C6452H9958N1722O2010S42
EXACT_MASS  145065.8205
MOL_WEIGHT  145155.1643
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC08
            Product: D09315<JP/US>
EFFICACY    Anti-inflammatory disease, Anti-IL-1 beta antibody
  DISEASE   Cryopyrin-associated periodic syndromes [DS:H00282]
            Tumor necrosis factor receptor associated periodic syndrome [DS:H00912]
            Hyperimmunoglobulin D syndrome /Mevalonate kinase deficiency [DS:H00206]
            Familial mediterranean fever [DS:H00288]
            Systemic juvenile idiopathic arthritis [DS:H01672]
  TYPE      Monoclonal antibody
TARGET      IL1B [HSA:3553] [KO:K04519]
  PATHWAY   hsa04010(3553)  MAPK signaling pathway
            hsa04060(3553)  Cytokine-cytokine receptor interaction
            hsa04621(3553)  NOD-like receptor signaling pathway
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC08 Canakinumab
                  D09315  Canakinumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Canakinumab
                 D09315  Canakinumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D09315  Canakinumab (USAN/INN); Canakinumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09315  Canakinumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09315  Canakinumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL1B
                 D09315  Canakinumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09315
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09315
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09315
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09315
DBLINKS     CAS: 914613-48-2
            PubChem: 96025995
///
